Terclara

Terclara is a topical cutaneous solution containing terbinafine hydrochloride (equivalent to 98 mg/mL terbinafine) developed for the treatment of mild to moderate fungal infections of the nails (onychomycosis) caused by dermatophytes and other terbinafine-sensitive fungi. It is indicated for adult use only and is applied once daily to affected fingernails or toenails, with typical treatment durations of about 6 months for fingernails and 9–12 months for toenails. The mechanism of action involves inhibition of fungal sterol biosynthesis at an early step, leading to ergosterol deficiency and intracellular accumulation of squalene, resulting in fungal cell death. Clinical trials have shown high efficacy rates with daily dosing regimens. Developed by Moberg Pharma, Terclara has market approval in 13 EU countries and is marketed as a leading product in Sweden and Norway[1][2][3][5][6].

Brand names

Terclara

Other names

MOB-015MOB015MOB 015Terclara 98 mg/mL cutaneous solution